Erschienen in:
10.08.2020 | Letters of Biomedical and Clinical Research
Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care
Erschienen in:
Clinical Rheumatology
|
Ausgabe 1/2021
Einloggen, um Zugang zu erhalten
Excerpt
The act of non-medical switching, defined as switching stable patients who are doing well with their current therapy from an originator biologic to its biosimilar, has been endorsed as a reasonable treatment strategy. The safety and efficacy of non-medical switching have been evaluated in randomized controlled and real-world evidence studies, with conflicting results [
1‐
3]. Treatment discontinuations among patients undergoing non-medical switch could be explained by many factors including the so-called
nocebo effect [
4,
5]. …